BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Mallinckrodt
Teva
AstraZeneca
Chinese Patent Office
Express Scripts
Cerilliant
Moodys
Colorcon
Federal Trade Commission

Generated: January 23, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,087,545

« Back to Dashboard

Summary for Patent: 4,087,545
Title: Hexahydro-dibenzo[b,d]pyran-9-ones as antiemetic drugs
Abstract:Use of 1-hydroxy-3-alkyl-6,6a,7,8,10,10a-hexahydro-9H-dibenzo[b,d]pyran-9-ones as antiemetic drugs.
Inventor(s): Archer; Robert A. (Indianapolis, IN), Lemberger; Louis (Indianapolis, IN)
Assignee: Eli Lilly and Company (Indianapolis, IN)
Application Number:05/658,437
Patent Claims: 1. A process for providing prevention and treatment of emesis and nausea in mammals which comprises administering to a nauseated mammal an anti-emetic dose of a compound represented by the formula ##STR9## wherein R' is either C.sub.7 -C.sub.10 normal alkyl or is the group ##STR10## wherein R" is C.sub.2 -C.sub.7 alkyl and R.sup.v is H or methyl, wherein both R groups are identical and are H or methyl and wherein R'" is H or C.sub.1 -C.sub.4 alkanoyl, in an amount effective to prevent nausea.

2. A process according to claim 1 in which a dose of from 0.1 to 100 mgs per day of the drug is administered.

3. A process according to claim 1 in which a dose of from 1 to 20 mgs. per day of the drug is administered.

4. A process according to claim 1 in which the drug is administered by the oral route.

5. A process according to claim 1 in which dl-trans-1-hydroxy-3-(1',1'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6- dimethyl-9H-dibenzo[b,d]pyran-9-one is administered.

6. A process according to claim 1 in which dl-trans-1-hydroxy-3-(1',2'-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6- dimethyl-9H-dibenzo[b,d]pyran-9-one is administered.

7. A process according to claim 1 in which dl-trans-1-hydroxy-3-(1'-methylheptyl)-6,6a,7,8,10,10a-hexahydro-6,6-dimet hyl-9H-dibenzo[b,d]pyran-9-one is administered.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Queensland Health
Chinese Patent Office
Express Scripts
Dow
Moodys
Teva
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot